WO2001055108A3 - Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2? - Google Patents

Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2? Download PDF

Info

Publication number
WO2001055108A3
WO2001055108A3 PCT/US2001/000011 US0100011W WO0155108A3 WO 2001055108 A3 WO2001055108 A3 WO 2001055108A3 US 0100011 W US0100011 W US 0100011W WO 0155108 A3 WO0155108 A3 WO 0155108A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammation
treatment
spl
inhibitors
glyoxylamide
Prior art date
Application number
PCT/US2001/000011
Other languages
English (en)
Other versions
WO2001055108A2 (fr
Inventor
Jerome Herbert Fleisch
William Louis Macias
Original Assignee
Lilly Co Eli
Jerome Herbert Fleisch
William Louis Macias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Jerome Herbert Fleisch, William Louis Macias filed Critical Lilly Co Eli
Priority to AU2001236440A priority Critical patent/AU2001236440A1/en
Publication of WO2001055108A2 publication Critical patent/WO2001055108A2/fr
Publication of WO2001055108A3 publication Critical patent/WO2001055108A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement d'inflammations consistant à administrer à un animal une quantité efficace sur le plan thérapeutique d'un inhibiteur sPLA2, tel qu'un 1H-indole-3-glyoxylamide.
PCT/US2001/000011 2000-01-25 2001-01-16 Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2? WO2001055108A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001236440A AU2001236440A1 (en) 2000-01-25 2001-01-16 Method for the treatment of inflammation with spla2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17790700P 2000-01-25 2000-01-25
US60/177,907 2000-01-25

Publications (2)

Publication Number Publication Date
WO2001055108A2 WO2001055108A2 (fr) 2001-08-02
WO2001055108A3 true WO2001055108A3 (fr) 2001-12-20

Family

ID=22650407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000011 WO2001055108A2 (fr) 2000-01-25 2001-01-16 Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2?

Country Status (2)

Country Link
AU (1) AU2001236440A1 (fr)
WO (1) WO2001055108A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003966A1 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
CA2686157A1 (fr) * 2007-05-03 2008-11-13 Joaquim Trias Traitement des maladies cardiovasculaires et de la dyslipidemie au moyen d'inhibiteurs de la phospholipase a<sb>2</sb> secretoire (spla<sb>2</sb>) et therapies combinees impliquant des inhibiteurs de la spla<sb>2</sb>
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016453A1 (fr) * 1997-09-26 1999-04-08 Eli Lilly And Company Methode de traitement de la mucoviscidose
WO1999044604A1 (fr) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Compositions pharmaceutiques contenant un [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate sodique, inhibiteur des phospholipases
WO1999057100A1 (fr) * 1998-05-01 1999-11-11 Eli Lilly And Company Composés inhibiteurs de spla2 pour traiter une maladie
WO2000002561A1 (fr) * 1998-07-13 2000-01-20 University Of South Florida Modulation de la voie de phospholipase a2 utilisee comme procede therapeutique
WO2000007591A1 (fr) * 1998-08-03 2000-02-17 Eli Lilly And Company INHIBITEURS DE sPLA2 DE TYPE INDOLE
WO2000069818A1 (fr) * 1999-05-12 2000-11-23 Eli Lilly And Company DERIVE DE MORPHOLINO-N-ETHYL ESTER D'UN INHIBITEUR INDOLE DE sPLA¿2?
WO2001005731A1 (fr) * 1999-07-19 2001-01-25 Garegin Oganesovich Karapetyan Procede d'immobilisation de composes physiologiquement actifs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016453A1 (fr) * 1997-09-26 1999-04-08 Eli Lilly And Company Methode de traitement de la mucoviscidose
WO1999044604A1 (fr) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Compositions pharmaceutiques contenant un [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate sodique, inhibiteur des phospholipases
WO1999057100A1 (fr) * 1998-05-01 1999-11-11 Eli Lilly And Company Composés inhibiteurs de spla2 pour traiter une maladie
WO2000002561A1 (fr) * 1998-07-13 2000-01-20 University Of South Florida Modulation de la voie de phospholipase a2 utilisee comme procede therapeutique
WO2000007591A1 (fr) * 1998-08-03 2000-02-17 Eli Lilly And Company INHIBITEURS DE sPLA2 DE TYPE INDOLE
WO2000069818A1 (fr) * 1999-05-12 2000-11-23 Eli Lilly And Company DERIVE DE MORPHOLINO-N-ETHYL ESTER D'UN INHIBITEUR INDOLE DE sPLA¿2?
WO2001005731A1 (fr) * 1999-07-19 2001-01-25 Garegin Oganesovich Karapetyan Procede d'immobilisation de composes physiologiquement actifs

Also Published As

Publication number Publication date
AU2001236440A1 (en) 2001-08-07
WO2001055108A2 (fr) 2001-08-02

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
YU5503A (sh) Nesteroidni supresori zapaljenja
WO2005046618A3 (fr) Methodes de traitement de l&#39;eczema
WO2004056307A3 (fr) Traitement de maladie par le biais d&#39;inhibiteurs de peptides antimicrobiens
WO2005046657A3 (fr) Methode de traitement de la maladie intestinale inflammatoire
WO2001056573A8 (fr) Utilisation d&#39;inhibiteurs de cox-2 en tant qu&#39;agents procinetiques gastriques
TW200510397A (en) Conjugated complement cascade inhibitors
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
WO2001085201A3 (fr) Utilisation d&#39;inhibiteurs il-18 pour le traitement et/ou la prevention de l&#39;atherosclerose
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
WO2003048122A3 (fr) Inhibiteurs de phospholipase a2 cytosolique
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
AU2003260778A1 (en) Treatment of pipes
SE0004101D0 (sv) New use
WO2001066101A3 (fr) Traitement du psoriasis
WO2001055108A3 (fr) Methode de traitement d&#39;inflammations au moyen d&#39;inhibiteurs spla¿2?
WO2001087281A3 (fr) Procede d&#39;amelioration de la fonction cognitive
WO2004060878A3 (fr) Inhibiteurs de phosphatases
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
WO2006133231A3 (fr) Traitement de maladies neurodegeneratives
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU2001274344A1 (en) Tissue inhibitors of matrix metalloproteinases
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU2001241630A1 (en) Treatment of inflammation with p20
IT1317073B1 (it) Esteri dell&#39;acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10416241

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP